Aridis Pharmaceuticals, Inc. (ARDS)

OTCMKTS · Delayed Price · Currency is USD

0.0002

0.00 (0.00%)

At close: Mar 3, 2026

100.00% (1Y)

Market Cap	10.66K
Revenue (ttm)	22.36M
Net Income (ttm)	-1.14M
Shares Out	53.32M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	10,252
Open	0.0002
Previous Close	n/a
Day's Range	0.0002 - 0.0002
52-Week Range	0.0000 - 0.0500
Beta	3,877.58
RSI	48.06
Earnings Date	n/a

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 37

Stock Exchange OTCMKTS

Ticker Symbol ARDS

Full Company Profile

Financial Performance

In 2022, Aridis Pharmaceuticals's revenue was $3.09 million, an increase of 101.37% compared to the previous year's $1.54 million. Losses were -$30.37 million, -34.43% less than in 2021.

Financial Statements

News

There is no news available yet.